Financials
Financial year 2026
anicells from Niel, company number BE0725459634, closed financial year 2026 with a result of € 79,113 after tax. For that financial year anicells recorded a gross margin of € 1.2 million and equity of € 184,634. Compared with financial year 2025, the result moved from € 53,313 to € 79,113. Profitable, and profit is growing. The buffer is growing. High debts against a small own buffer. The most recent annual accounts were filed with the National Bank of Belgium on October 15, 2026.
€ 184,634
▲ 75% vs 2025
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 79,113
▲ 48% vs 2025
Profit after tax over the fiscal year.
€ 570,573
▲ 26% vs 2025
Cash and bank balances on the last day of the fiscal year.
Stays in the company
No dividend for 2026. Retained profit grew to € 178,434.
People and assets in 2026
13.8
Average over the fiscal year, from the social balance sheet.
€ 870,103
▲ 31% vs 2025
€ 63,100 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.
€ 47,303
▼ 23% vs 2025
Book value of vehicles, furniture and equipment.
Debts at end 2026
€ 450,000
€ 100,000 is repaid this year. At this pace the long-term loan is gone in ≈ 5 years.
€ 369,600
▼ 3% vs 2025
Supplier invoices still open on the last day of the fiscal year.
€ 226,232
▲ 28% vs 2025
Taxes, VAT and social contributions still to pay.
| 2023 | 2024 | 2025 | 2026 | Change 2025 → 2026 | |
|---|---|---|---|---|---|
| Gross margin | € 288,739 | € 445,993 | € 983,662 | € 1,235,971 | ▲ 26% |
| Profit after taxes | € 4,411 | € 30,149 | € 53,313 | € 79,113 | ▲ 48% |
| Equity | € 22,059 | € 52,207 | € 105,520 | € 184,634 | ▲ 75% |
| Total debts | € 771,162 | € 1,396,114 | € 1,704,803 | € 1,638,638 | ▼ 4% |
| Cash | € 94,488 | € 421,290 | € 454,038 | € 570,573 | ▲ 26% |
| Retained profit | € 15,859 | € 46,007 | € 99,320 | € 178,434 | ▲ 80% |
| Bank debt | € 450,000 | € 450,000 | € 450,000 | € 450,000 | |
| Balance sheet total | € 793,220 | € 1,448,321 | € 1,810,323 | € 1,823,271 | ▲ 1% |
| Employees (FTE) | - | - | - | 13.8 |
Key figures of anicells, fiscal years 2023 to 2026, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2027) expected before 31 October 2027.
What happened to anicells?
What happened at anicells in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2026: profit of € 79,113 (▲ 48% vs 2025). Source: NBB ↗
- New establishment in Niel. KBO
- Start of the company according to the CBE. KBO
In short
From € 4,411 profit in 2023 to € 79,113 profit in 2026.
Paid € 63,491 in corporate taxes since 2023.
Best year ever: 2026, with € 79,113 profit.
On average € 89,600 of value added per employee in 2026.
Management
Behind anicells is Nathalie Cools.
Directors
According to the 2026 annual accounts
Nathalie Cools
Director
Establishments
Establishment units
Physical locations of this company
Galileilaan 21
2845 Niel
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 4 companies are registered at this address.
All companies at this address →What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Website
Technologies
Hosting & Email
Email provider
Microsoft 365
Hosting
COMBELL-AS, BE
Domain
Domain
anicells.com
Registered
2018-02-28
Registrar
Ascio Technologies, Inc. Danmark - Filial af Ascio technologies, Inc. USA
Expires
2027-02-28
Website info
Features
Security
Network
Details
- Company number
- 0725.459.634
- VAT number
- BE 0725.459.634
- Registered office
- Galileilaan 21, 2845 Niel
- Names & denominations
- anicells
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 17 April 2019
- Peppol
- Active · Active since 21 Oct 2026
- Contact
- anicells.com
- Activities · NACE
Vervaardiging van overige farmaceutische producten
Speur- en ontwikkelingswerk op biotechnologisch gebied